We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.
- Authors
Jean-Pierre, Vincent; Sorlin, Pauline; Pantel, Alix; Chiron, Raphaël; Lavigne, Jean-Philippe; Jeannot, Katy; Marchandin, Hélène; Amara, Marlène; Cadot, Lucile; Dauwalder, Olivier; Degand, Nicolas; Demar, Magalie; Dupin, Clarisse; Fangous, Marie-Sarah; Franczak, Claire; Garnier, Fabien; Guiet, Pascal; Guinard, Jérôme; Hombrouck-Alet, Cécile; Kaoula, Atika
- Abstract
Background: Achromobacter spp. are opportunistic pathogens, mostly infecting immunocompromised patients and patients with cystic fibrosis (CF) and considered as difficult-to-treat pathogens due to both intrinsic resistance and the possibility of acquired antimicrobial resistance. Species identification remains challenging leading to imprecise descriptions of resistance in each taxon. Cefiderocol is a broad-spectrum siderophore cephalosporin increasingly used in the management of Achromobacter infections for which susceptibility data remain scarce. We aimed to describe the susceptibility to cefiderocol of a collection of Achromobacter strains encompassing different species and isolation sources from CF or non-CF (NCF) patients. Methods: We studied 230 Achromobacter strains (67 from CF, 163 from NCF patients) identified by nrdA gene-based analysis, with available susceptibility data for piperacillin–tazobactam, meropenem and trimethoprim–sulfamethoxazole. Minimal inhibitory concentrations (MICs) of cefiderocol were determined using the broth microdilution reference method according to EUCAST guidelines. Results: Strains belonged to 15 species. A. xylosoxidans represented the main species (71.3%). MICs ranged from ≤ 0.015 to 16 mg/L with MIC50/90 of ≤ 0.015/0.5 mg/L overall and 0.125/2 mg/L against 27 (11.7%) meropenem-non-susceptible strains. Cefiderocol MICs were not related to CF/NCF origin or species although A. xylosoxidans MICs were statistically lower than those of other species considered as a whole. Considering the EUCAST non-species related breakpoint (2 mg/L), 228 strains (99.1%) were susceptible to cefiderocol. The two cefiderocol-resistant strains (A. xylosoxidans from CF patients) represented 3.7% of meropenem-non-susceptible strains and 12.5% of MDR strains. Conclusions: Cefiderocol exhibited excellent in vitro activity against a large collection of accurately identified Achromobacter strains, irrespective of species and origin.
- Subjects
ACHROMOBACTER; BIOLOGICAL evolution; MEROPENEM; CYSTIC fibrosis; IMMUNOCOMPROMISED patients; DRUG resistance in microorganisms; COLLECTIONS
- Publication
Annals of Clinical Microbiology & Antimicrobials, 2024, Vol 23, Issue 1, p1
- ISSN
1476-0711
- Publication type
Article
- DOI
10.1186/s12941-024-00709-z